Target Price Playground
GSK
$47.76
Swing & Horizon Engine
Need pre-expiry P&L (+3d / +5d), multi-leg ratios, or hedged overlays on GSK? Launch with your exact active legs & +8.0% target.
Forward Projection
If price hits $52 by Jan 15
Multi-Option Simulator
Pre-expiry +3d/+5d & Overlays
Options Architect
Multi-leg solver & Greeks
1x1x1 Structure
Reverse Time-Diagonal + Call
๐ Strategy
Long Stock
Long Call
Long Put
Bull Call Spread
Bear Put Spread
Bear Call Credit Spread
Bull Put Credit Spread
Covered Call
Protective Put
Cash-Secured Put
Diagonal Put Spread
Long Straddle
Own stock, sell OTM call for income. Caps upside.
๐ฏ Target
1-Click Institutional Target Anchors:
56d from today
โ๏ธ Legs
LONG 100 SHARES
@ $47.76 ยท ฮ 1.00
SHORT CALL ยท $52 ยท Jan '27
Qty 1 ยท Premium $0.88 ยท ฮ 0.27
P&L at Expiry
Stock (100 sh)
Covered Call
Now
Target
๐ก Stock vs Options at Target
If GSK hits $52 by Jan 15: the covered call returns +$470 (10.0%) on $4,688 risked, vs +$382 (8.0%) for 100 shares on $4,776. Options give 1.2ร capital efficiency.
๐ Expiry & Gamma Wall Alignment
Options expire Jan 15, 2027 (56 days out). P&L shown is the value at expiry if GSK is at $52.
๐ Projected Return
P&L if GSK hits $52 by Jan 15
+$470
+10.0% on $4,688 risked
Max Profit
+$512
If the stock โฅ $52 at expiry
Max Loss
โ$4,688
If stock โ $0 (minus premium received)
Break-even
$46.88
-1.85% from spot
Prob. of Profit at Expiry (PoP)
56.3%
Above breakeven ($46.88)
ยท Touch Target: 50%
Net ฮ / ฮ / V
72.78 / 1.81 / -6.21
per spread, per $1 move / day / vol pt
๐ P&L Scenarios โ what happens at different prices and dates
| GSK Price | Today | +3d (Nov 23) | +7d (Nov 27) | Dec 8 | Dec 27 | Jan 15 (exp) |
|---|---|---|---|---|---|---|
| $38 (-20%) | -$868 | -$868 | -$867 | -$867 | -$867 | -$867 |
| $41 (-15%) | -$632 | -$631 | -$630 | -$629 | -$628 | -$628 |
| $43 (-10%) | -$404 | -$402 | -$400 | -$395 | -$390 | -$390 |
| $45 (-5%) | -$190 | -$186 | -$182 | -$170 | -$154 | -$151 |
| $47 (-2%) | -$73 | -$68 | -$62 | -$45 | -$18 | -$8 |
| $48 (0%) โ spot | -$0 | +$5 | +$13 | +$33 | +$69 | +$88 |
| $49 (+2%) | +$67 | +$73 | +$82 | +$106 | +$151 | +$184 |
| $50 (+5%) | +$156 | +$163 | +$173 | +$201 | +$258 | +$327 |
| $52 (+8%) โ target | +$232 | +$239 | +$249 | +$280 | +$343 | +$470 |
| $53 (+10%) | +$275 | +$282 | +$293 | +$323 | +$388 | +$512 |
| $55 (+15%) | +$357 | +$365 | +$374 | +$403 | +$459 | +$512 |
| $57 (+20%) | +$411 | +$417 | +$425 | +$448 | +$488 | +$512 |
Uses GSK's current IV for repricing. P&L includes all legs (stock + options). Qty: 1x.